EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

Updated Guidelines for the Diagnosis and Treatment of Endometrial Carcinoma: The Polish Society of Gynecological Oncology (2025v)

Jacek J Sznurkowski iD, Lubomir Bodnar iD, Anna Dańska-Bidzińska, Andrzej Marszałek, Pawel Blecharz, Anita Chudecka-Głaz, Dagmara Klasa-Mazurkiewicz, Artur Kowalik iD, Agnieszka Zołciak-Siwinska, Aleksandra Zielinska iD, Mariusz Bidziński iD, Włodzimierz Sawicki iD

Current Oncology · 09.06.2025 · 32 (6) · 340

DOI: 10.3390/curroncol32060340 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Current Oncology, online erschienen am 09.06.2025. Verfasst von Jacek J Sznurkowski und 11 weiteren Autor:innen. Beteiligte Einrichtung: Profesor Sznurkowski Podmiot Leczniczy, ul. Stefana Żeromskiego 23A, 81-246 Gdynia, Poland. Hauptthemen laut MEDLINE: Endometrial Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In 2023, the Polish Society of Gynecologic Oncology (PSGO) published clinical recommendations for the diagnosis, treatment, and care of women with endometrial cancer (EC), developed using the AGREE II (Appraisal of Guidelines for Research and Evaluation) tool. A 2025 update was initiated in response to new evidence, particularly regarding systemic therapies for metastatic, advanced, or recurrent EC, and the introduction of an updated FIGO classification. A targeted literature review identified relevant phase III clinical trials and systematic reviews, including RUBY, GY-018, AtTend, and DUO-E. These trials were critically assessed by an Expert Panel in accordance with the AGREE II methodology. Updated recommendations were formulated based on this evidence, with a comparative analysis of the old and new FIGO staging systems and visual updates to treatment pathways. Key changes include the addition of immunotherapy (I/O) plus chemotherapy (CHTH) as first-line treatment for all molecular subtypes of high-grade endometrioid and non-endometrioid carcinomas, replacing chemotherapy alone. For MMRp-positive cases, the 2025 version introduces the use of Olaparib alongside Durvalumab and CHTH. HER2-positive MMRp serous carcinoma remains eligible for trastuzumab in combination with CHTH. Second-line treatment guidance remains unchanged for patients who did not receive I/O plus CHTH initially. However, options for those previously treated with this combination are still under evaluation. This update ensures alignment with the latest international standards and reinforces evidence-based, personalized care for EC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsFemaleHumansMedical OncologyPolandSocieties, Medical

Stichwörter der Autor:innen

AGREEI/OMMRDNSMPPOLETP53abnadjuvantdiagnosisendometrial cancerguidelinesimmunotherapysystemictargeted therapyupdate

Autor:innen und Institutionen

  • Profesor Sznurkowski Podmiot Leczniczy, ul. Stefana Żeromskiego 23A, 81-246 Gdynia, Poland.
  • Faculty of Medical and Health Sciences, University in Siedlce, 08-110 Siedlce, Poland.
  • Department of Gynaecological Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 00-001 Warsaw, Poland.
  • Department of Tumor Pathology and Prophylaxis, Poznan University of Medical Sciences, 60-806 Poznan, Poland.
  • Department of Tumor Pathology, Greater Poland Cancer Center in Poznan, 61-866 Poznan, Poland.
  • Department of Gynaecologic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch, 00-001 Warsaw, Poland.

ORCID-Profile: Jacek J Sznurkowski, Lubomir Bodnar, Artur Kowalik, Aleksandra Zielinska, Mariusz Bidziński, Włodzimierz Sawicki

Zitieren

APA

Sznurkowski, J. J., Bodnar, L., Dańska-Bidzińska, A., Marszałek, A., Blecharz, P., Chudecka-Głaz, A., Klasa-Mazurkiewicz, D., Kowalik, A., Zołciak-Siwinska, A., Zielinska, A., Bidziński, M., & Sawicki, W. (2025). Updated Guidelines for the Diagnosis and Treatment of Endometrial Carcinoma: The Polish Society of Gynecological Oncology (2025v). Current Oncology, 32(6), 340. https://doi.org/10.3390/curroncol32060340

Vancouver

Sznurkowski JJ, Bodnar L, Dańska-Bidzińska A, Marszałek A, Blecharz P, Chudecka-Głaz A, et al. Updated Guidelines for the Diagnosis and Treatment of Endometrial Carcinoma: The Polish Society of Gynecological Oncology (2025v). Current Oncology. 2025;32(6):340. doi:10.3390/curroncol32060340

BibTeX
@article{Sznurkowski2025,
  author = {Sznurkowski, Jacek J and Bodnar, Lubomir and Dańska-Bidzińska, Anna and Marszałek, Andrzej and Blecharz, Pawel and Chudecka-Głaz, Anita and Klasa-Mazurkiewicz, Dagmara and Kowalik, Artur and Zołciak-Siwinska, Agnieszka and Zielinska, Aleksandra and Bidziński, Mariusz and Sawicki, Włodzimierz},
  title = {Updated Guidelines for the Diagnosis and Treatment of Endometrial Carcinoma: The Polish Society of Gynecological Oncology (2025v)},
  journal = {Current Oncology},
  year = {2025},
  volume = {32},
  number = {6},
  pages = {340},
  doi = {10.3390/curroncol32060340}
}
Kostenlos starten →